{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T08:21:56Z","timestamp":1790842916430,"version":"4.1.0"},"reference-count":61,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Immunology"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1016\/j.molimm.2014.09.014","type":"journal-article","created":{"date-parts":[[2014,10,9]],"date-time":"2014-10-09T07:22:04Z","timestamp":1412839324000},"page":"107-116","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":134,"special_numbering":"PA","title":["Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies"],"prefix":"10.1016","volume":"67","author":[{"given":"Boris","family":"Shor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Peter","family":"Gerber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Puja","family":"Sapra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.molimm.2014.09.014_bib0005","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1200\/JCO.2009.25.1900","article-title":"Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study","volume":"28","author":"Advani","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.molimm.2014.09.014_bib0010","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.semradonc.2013.08.004","article-title":"Comparative effectiveness research in radiation oncology: stereotactic radiosurgery, hypofractionation, and brachytherapy","volume":"24","author":"Aneja","year":"2014","journal-title":"Semin. Radiat. Oncol."},{"key":"10.1016\/j.molimm.2014.09.014_bib0015","doi-asserted-by":"crossref","first-page":"5733","DOI":"10.1002\/cncr.27622","article-title":"A phase 1 study of weekly dosing of trastuzumab emtansine (T-DM1) in patients with advanced human epidermal growth factor 2-positive breast cancer","volume":"118","author":"Beeram","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.molimm.2014.09.014_bib0020","doi-asserted-by":"crossref","first-page":"4412","DOI":"10.1073\/pnas.89.10.4412","article-title":"Demonstration of nuclear compartmentalization of glutathione in hepatocytes","volume":"89","author":"Bellomo","year":"1992","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molimm.2014.09.014_bib0025","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/sj.leu.2401663","article-title":"Monoclonal antibodies to the myeloid stem cells: therapeutic implications of CMA-676, a humanized anti-CD33 antibody calicheamicin conjugate","volume":"14","author":"Bernstein","year":"2000","journal-title":"Leukemia"},{"key":"10.1016\/j.molimm.2014.09.014_bib0030","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1200\/JCO.2010.31.4310","article-title":"Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial","volume":"29","author":"Burnett","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.molimm.2014.09.014_bib0035","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/S0140-6736(12)60485-1","article-title":"Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study","volume":"379","author":"Castaigne","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.molimm.2014.09.014_bib0040","series-title":"Oxford Textbook of Medicine","article-title":"Cancer chemotherapy and radiation therapy","author":"Chabner","year":"2010"},{"key":"10.1016\/j.molimm.2014.09.014_bib0045","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1517\/14712598.4.9.1445","article-title":"Tumour-targeted chemotherapy with immunoconjugates of calicheamicin","volume":"4","author":"Damle","year":"2004","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.molimm.2014.09.014_bib0050","doi-asserted-by":"crossref","first-page":"R204","DOI":"10.1186\/ar3179","article-title":"Epratuzumab targeting of CD22 affects adhesion molecule expression and migration of B-cells in systemic lupus erythematosus","volume":"12","author":"Daridon","year":"2010","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.molimm.2014.09.014_bib0055","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/leu.2011.206","article-title":"The novel calicheamicin-conjugated CD22 antibody inotuzumab ozogamicin (CMC-544) effectively kills primary pediatric acute lymphoblastic leukemia cells","volume":"26","author":"de Vries","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.molimm.2014.09.014_bib0060","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1021\/tx00027a001","article-title":"Free-radical mechanisms involved in the formation of sequence-dependent bistranded DNA lesions by the antitumor antibiotics bleomycin, neocarzinostatin, and calicheamicin","volume":"5","author":"Dedon","year":"1992","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.molimm.2014.09.014_bib0065","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1182\/blood-2003-07-2466","article-title":"Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies","volume":"103","author":"DiJoseph","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.molimm.2014.09.014_bib0070","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1038\/sj.leu.2404866","article-title":"Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia","volume":"21","author":"Dijoseph","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.molimm.2014.09.014_bib0075","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s00280-010-1342-9","article-title":"Preclinical anti-tumor activity of antibody-targeted chemotherapy with CMC-544 (inotuzumab ozogamicin), a CD22-specific immunoconjugate of calicheamicin, compared with non-targeted combination chemotherapy with CVP or CHOP","volume":"67","author":"DiJoseph","year":"2011","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.molimm.2014.09.014_bib0080","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1158\/1078-0432.CCR-05-1905","article-title":"Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin's B-cell lymphoma","volume":"12","author":"DiJoseph","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.molimm.2014.09.014_bib0085","doi-asserted-by":"crossref","first-page":"8620","DOI":"10.1158\/1078-0432.CCR-04-1134","article-title":"Potent and specific antitumor efficacy of CMC-544, a CD22-targeted immunoconjugate of calicheamicin, against systemically disseminated B-cell lymphoma","volume":"10","author":"DiJoseph","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.molimm.2014.09.014_bib0090","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00262-004-0572-2","article-title":"Antibody-targeted chemotherapy of B-cell lymphoma using calicheamicin conjugated to murine or humanized antibody against CD22","volume":"54","author":"DiJoseph","year":"2005","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.molimm.2014.09.014_bib0095","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1126\/science.7618087","article-title":"A role in B cell activation for CD22 and the protein tyrosine phosphatase SHP","volume":"269","author":"Doody","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.molimm.2014.09.014_bib0100","doi-asserted-by":"crossref","first-page":"4470","DOI":"10.4049\/jimmunol.136.12.4470","article-title":"HD39 (B3), a B lineage-restricted antigen whose cell surface expression is limited to resting and activated human B lymphocytes","volume":"136","author":"Dorken","year":"1986","journal-title":"J. Immunol."},{"key":"10.1016\/j.molimm.2014.09.014_bib0105","doi-asserted-by":"crossref","first-page":"7464","DOI":"10.1073\/pnas.88.17.7464","article-title":"The carbohydrate domain of calicheamicin gamma I1 determines its sequence specificity for DNA cleavage","volume":"88","author":"Drak","year":"1991","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molimm.2014.09.014_bib0110","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1002\/chir.20990","article-title":"Structural and conformational features relevant to the anti-tumor activity of calicheamicin gamma 1I","volume":"23","author":"Ellestad","year":"2011","journal-title":"Chirality"},{"key":"10.1016\/j.molimm.2014.09.014_bib0115","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1158\/1078-0432.CCR-11-1425","article-title":"A phase I weekly dosing study of brentuximab vedotin in patients with relapsed\/refractory CD30-positive hematologic malignancies","volume":"18","author":"Fanale","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.molimm.2014.09.014_bib0120","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1200\/JCO.2012.42.7211","article-title":"Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I\/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab","volume":"31","author":"Fayad","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.molimm.2014.09.014_bib0125","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1039\/c3np20113a","article-title":"The antibody\u2013drug conjugate: an enabling modality for natural product-based cancer therapeutics","volume":"30","author":"Gerber","year":"2013","journal-title":"Nat. Prod. Rep."},{"key":"10.1016\/j.molimm.2014.09.014_bib0130","first-page":"324","article-title":"Inotuzumab ozogamicin in patients with indolent b-cell non-Hodgkin lymphoma refractory to Rituximab and chemotherapy or radioimmunotherapy","volume":"97","author":"Goy","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.molimm.2014.09.014_bib0135","series-title":"Enediyne Antibiotics as Antitumor Agents","first-page":"17","article-title":"The biochemical induction assay and its application in the detection of the calicheamicins","author":"Greenstein","year":"1993"},{"key":"10.1016\/j.molimm.2014.09.014_bib0140","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1021\/bc0100206","article-title":"An anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Choice of linker","volume":"13","author":"Hamann","year":"2002","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.molimm.2014.09.014_bib0145","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1021\/bc010021y","article-title":"Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia","volume":"13","author":"Hamann","year":"2002","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.molimm.2014.09.014_bib0150","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1182\/blood-2012-06-438002","article-title":"Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia","volume":"121","author":"Haso","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.molimm.2014.09.014_bib0155","doi-asserted-by":"crossref","first-page":"9203","DOI":"10.1073\/pnas.91.20.9203","article-title":"Specific inhibition of formation of transcription complexes by a calicheamicin oligosaccharide: a paradigm for the development of transcriptional antagonists","volume":"91","author":"Ho","year":"1994","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molimm.2014.09.014_bib0160","series-title":"SEER Cancer Statistics Review (CSR) 1975\u20132010","year":"2013"},{"key":"10.1016\/j.molimm.2014.09.014_bib0165","doi-asserted-by":"crossref","first-page":"10506","DOI":"10.1073\/pnas.92.23.10506","article-title":"Calicheamicin\u2013DNA complexes: warhead alignment and saccharide recognition of the minor groove","volume":"92","author":"Ikemoto","year":"1995","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molimm.2014.09.014_bib0170","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.4049\/jimmunol.170.7.3534","article-title":"The B cell coreceptor CD22 associates with AP50, a clathrin-coated pit adapter protein, via tyrosine-dependent interaction","volume":"170","author":"John","year":"2003","journal-title":"J. Immunol."},{"key":"10.1016\/j.molimm.2014.09.014_bib0175","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S1470-2045(11)70386-2","article-title":"Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study","volume":"13","author":"Kantarjian","year":"2012","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.molimm.2014.09.014_bib0180","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1002\/cncr.28136","article-title":"Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia","volume":"119","author":"Kantarjian","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.molimm.2014.09.014_bib0185","series-title":"The Calicheamicins","first-page":"31","author":"Lee","year":"1993"},{"key":"10.1016\/j.molimm.2014.09.014_bib0190","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1021\/ja00029a030","article-title":"Calicheamicins, a novel family of antitumor antibiotics. 4. Structure elucidation of calicheamicins .beta.1Br, .gamma.1Br, .alpha.2I, .alpha.3I, .beta.1I.gamma.1I, and .delta.1I","volume":"114","author":"Lee","year":"1992","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.molimm.2014.09.014_bib0195","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.7164\/antibiotics.42.1070","article-title":"Calicheamicins, a novel family of antitumor antibiotics, 3. Isolation, purification and characterization of calicheamicins beta 1Br, gamma 1Br, alpha 2I, alpha 3I, beta 1I, gamma 1I and delta 1I","volume":"42","author":"Lee","year":"1989","journal-title":"J. Antibiot."},{"key":"10.1016\/j.molimm.2014.09.014_bib0200","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1023\/A:1014414520282","article-title":"General pharmacokinetic model for drugs exhibiting target-mediated drug disposition","volume":"28","author":"Mager","year":"2001","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.molimm.2014.09.014_bib0205","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1309\/AJCPFMV43IFPRTWK","article-title":"Is the aberrant expression of p53 by immunocytochemistry a surrogate marker of TP53 mutation and\/or deletion in chronic lymphocytic leukemia?","volume":"135","author":"Marinelli","year":"2011","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.molimm.2014.09.014_bib0210","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1124\/jpet.300.1.346","article-title":"Pharmacokinetics of murine anti-human CD3 antibodies in man are determined by the disappearance of target antigen","volume":"300","author":"Meijer","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.molimm.2014.09.014_bib0215","doi-asserted-by":"crossref","first-page":"5881","DOI":"10.1073\/pnas.90.13.5881","article-title":"Chemistry and biology of natural and designed enediynes","volume":"90","author":"Nicolaou","year":"1993","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molimm.2014.09.014_bib0220","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/j.1600-065X.2009.00801.x","article-title":"CD22 and Siglec-G: B-cell inhibitory receptors with distinct functions","volume":"230","author":"Nitschke","year":"2009","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.molimm.2014.09.014_bib0225","series-title":"ASH Annual Meeting Abstract, vol. 120","first-page":"671","article-title":"Experience with 2 dose schedules of inotuzumab ozogamicin, single dose, and weekly, in refractory-relapsed acute lymphocytic leukemia (ALL)","author":"O\u2019Brien","year":"2012"},{"key":"10.1016\/j.molimm.2014.09.014_bib0230","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1111\/j.1349-7006.2012.02241.x","article-title":"Phase I study of anti-CD22 immunoconjugate inotuzumab ozogamicin plus rituximab in relapsed\/refractory B-cell non-Hodgkin lymphoma","volume":"103","author":"Ogura","year":"2012","journal-title":"Cancer Sci."},{"key":"10.1016\/j.molimm.2014.09.014_bib0235","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1111\/j.1349-7006.2010.01601.x","article-title":"Phase I study of inotuzumab ozogamicin (CMC-544) in Japanese patients with follicular lymphoma pretreated with rituximab-based therapy","volume":"101","author":"Ogura","year":"2010","journal-title":"Cancer Sci."},{"key":"10.1016\/j.molimm.2014.09.014_bib0240","series-title":"ASH Annual Meeting Abstract, vol. 118","first-page":"3715","article-title":"An open-label, phase i study of r-cvp in combination with inotuzumab ozogamicin in patients with relapsed\/refractory CD22-positive B-cell non-Hodgkin lymphoma","author":"Ogura","year":"2011"},{"key":"10.1016\/j.molimm.2014.09.014_bib0245","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1080\/08820130500496878","article-title":"A quantitative exploration of surface antigen expression in common B-cell malignancies using flow cytometry","volume":"35","author":"Olejniczak","year":"2006","journal-title":"Immunol. Investig."},{"key":"10.1016\/j.molimm.2014.09.014_bib0250","series-title":"ASH Annual Meeting Abstract, vol. 114","first-page":"790","author":"Petersdorf","year":"2009"},{"key":"10.1016\/j.molimm.2014.09.014_bib0255","series-title":"Pfizer Discontinues Phase 3 Study of Inotuzumab Ozogamicin in Relapsed or Refractory Aggressive Non-Hodgkin Lymphoma (NHL) Due to Futility","author":"Pfizer","year":"2013"},{"key":"10.1016\/j.molimm.2014.09.014_bib0260","doi-asserted-by":"crossref","first-page":"325","DOI":"10.3109\/10428194.2010.529206","article-title":"Surface antigens analysis reveals significant expression of candidate targets for immunotherapy in adult acute lymphoid leukemia","volume":"52","author":"Piccaluga","year":"2011","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.molimm.2014.09.014_bib0265","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.3109\/10428194.2011.559668","article-title":"Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases","volume":"52","author":"Raponi","year":"2011","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.molimm.2014.09.014_bib0270","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1002\/pbc.24721","article-title":"Initial experience with CMC-544 (inotuzumab ozogamicin) in pediatric patients with relapsed B-cell acute lymphoblastic leukemia","volume":"61","author":"Rytting","year":"2014","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.molimm.2014.09.014_bib0275","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1586\/17512433.2013.827405","article-title":"Preclinical and clinical pharmacokinetic\/pharmacodynamic considerations for antibody\u2013drug conjugates","volume":"6","author":"Sapra","year":"2013","journal-title":"Exp. Rev. Clin. Pharmacol."},{"key":"10.1016\/j.molimm.2014.09.014_bib0280","series-title":"Drug Delivery in Oncology","first-page":"395","article-title":"Calicheamicin antibody\u2013drug conjugates and beyond","author":"Sapra","year":"2011"},{"key":"10.1016\/j.molimm.2014.09.014_bib0285","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3322\/caac.21166","article-title":"Cancer statistics","volume":"63","author":"Siegel","year":"2013","journal-title":"Cancer J. Clin."},{"key":"10.1016\/j.molimm.2014.09.014_bib0290","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.2174\/1381612003398564","article-title":"Understanding and exploiting nature's chemical arsenal: the past, present and future of calicheamicin research","volume":"6","author":"Thorson","year":"2000","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.molimm.2014.09.014_bib0295","series-title":"ASH Annual Meeting Abstract, vol. 116","first-page":"2883","article-title":"Anti-CD22 Immunoconjugate inotuzumab ozogamicin (CMC-544)+ Rituximab in relapsed DLBCL patients followed by stem cell transplantation: preliminary safety and efficacy","author":"Wagner-Johnston","year":"2010"},{"key":"10.1016\/j.molimm.2014.09.014_bib0300","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1126\/science.2717946","article-title":"Calicheamicin gamma 1I and DNA: molecular recognition process responsible for site-specificity","volume":"244","author":"Zein","year":"1989","journal-title":"Science"},{"key":"10.1016\/j.molimm.2014.09.014_bib0305","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1126\/science.3240341","article-title":"Calicheamicin gamma 1I: an antitumor antibiotic that cleaves double-stranded DNA site specifically","volume":"240","author":"Zein","year":"1988","journal-title":"Science"}],"container-title":["Molecular Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161589014002594?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161589014002594?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T04:44:29Z","timestamp":1689569069000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161589014002594"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":61,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["S0161589014002594"],"URL":"https:\/\/doi.org\/10.1016\/j.molimm.2014.09.014","relation":{},"ISSN":["0161-5890"],"issn-type":[{"value":"0161-5890","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies","name":"articletitle","label":"Article Title"},{"value":"Molecular Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.molimm.2014.09.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}